

Research Methodology and Medical Treatment Guidelines

June 6, 2022 - Montana DLI

INTRODUCTION


Daniel Vigil, MD, MPH

- ▶ Preventive Medicine Physician
- ▶ Masters in Public Health
 - ▶ Focus in Epidemiology & Biostatistics
- ▶ Senior Research Methodologist
 - ▶ Colorado Division of Workers' Comp.
(Medical Treatment Guidelines)

INTRODUCTION

Presentation Goals

- ▶ Why we create the MTGs
- ▶ The Colorado DOWC process
- ▶ Study quality / confidence based on study type and risk of bias



Why Evidence-Based Medical Treatment Guidelines?

WHY EVIDENCE-BASED MTGs?

Our goal is to make **decisions** that are **most likely** to achieve our **desired outcomes**.

WHY EVIDENCE-BASED MTGs?

**Desired
outcomes**
in
Workers'
Comp

- Healing →
Functional improvement →
Return to work
- Safety
- Resources / Cost-effectiveness

WHY EVIDENCE-BASED MTGs?

Medical **Decisions** in Workers' Comp

- Treatment options
 - When and for whom
 - How much, how long
 - When to try something different
- Diagnostic approaches

WHY EVIDENCE-BASED MTGs?

For these types of decisions,
medical research is a
valuable information source.

WHY EVIDENCE-BASED MTGs?

But there's a lot of research
- of varying reliability –
how do we navigate that?


WHY EVIDENCE-BASED MTGs?

How do we navigate that?

- ▶ It's often complicated
 - ▶ Specialized knowledge and experience
 - ▶ It's time consuming

OUR AIMS FOR THE MTGs

- ▶ Provide best evidence on available medical treatments
- ▶ Weigh appropriateness of treatment relative to functional outcomes
- ▶ Address emerging treatments and diagnostics
- ▶ Create actionable recommendations



Phases of the Colorado DOWC MTG Process

PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ Finding and selecting studies
- ▶ Evaluating individual studies
- ▶ Combining evidence from multiple studies
- ▶ Writing recommendations and guidance
- ▶ Task Force process
- ▶ Advisory Panel and public input process

PHASES OF THE MTG PROCESS

▶ **Expert interviews and scoping**

- ▶ What topics should we review?

- ▶ Specify using PICO questions.

- ▶ Population (including the medical condition)

- ▶ Intervention (the treatment being studied)

- ▶ Comparison (typically a traditional/proven treatment)

- ▶ Outcome (function, pain, adverse events)

- ▶ Timing (how long after treatment)

PHASES OF THE MTG PROCESS

▶ **Expert interviews and scoping**

- ▶ Occ Med and PM&R Physicians
- ▶ Physical and Occupational Therapists and Physiatrists
- ▶ Psychiatrists and Psychologists
- ▶ Claimant's and Respondent's Attorneys
- ▶ Other Medical, Government, and Insurance Professionals

PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ **Finding and selecting studies**
- ▶ Evaluating individual studies
- ▶ Combining evidence from multiple studies
- ▶ Writing recommendations and guidance
- ▶ Task Force process
- ▶ Advisory Panel and public input process

PHASES OF THE MTG PROCESS

- ▶ **Finding and selecting studies**
 - ▶ Systematic search
 - ▶ PubMed and Cochrane Databases
 - ▶ Detailed search terms

SEARCH TERMS

((cam[sb] OR Vertebroplasty[mh] OR "Cognitive Behavioral Therapy"[mh] OR "Combined Modality Therapy"[mh] OR Traction[mh] OR Laminectomy[mh] OR "Diskectomy, Percutaneous"[mh] OR "Diskectomy/methods"[MAJR] OR ("Injections"[mh] AND "Adrenal Cortex Hormones/pharmacology"[mh]) OR "Injections,Spinal"[mh] OR "directional preference" OR "centralization" OR "Spinal Fusion"[mh] OR "Low-Level Light Therapy"[mh] OR "Smoking Cessation" OR "Lumbar discography" OR myelography[mh] OR "Diathermy"[mh] OR "Nerve Block"[mh] OR "orthotic devices"[mh] OR Arthroplasty[mh] OR Phonophoresis[mh] OR "Decompression, Surgical"[mh] OR "interferential therapy" OR "interferential current therapy" OR "Electric Stimulation Therapy"[mh] OR "Vax-D" OR "McKenzie Assessment" OR "infrared therapy" OR "ergonomic" OR "Workers' Compensation"[mh] OR "Return to Work"[mh] OR "Occupational diseases"[mh] OR "Occupational Health"[mh] OR "diagnostic imaging" OR "Analgesics"[mh] OR "Spinal Stenosis" OR "Radiculopathy" OR "Patient Education as Topic"[mh] OR "Conservative Treatment"[mh]) OR "Physical Therapy Modalities"[mh] AND (back[mh] OR neck[mh] OR "Back Pain"[mh] OR "Neck Pain"[mh] OR Sacroiliac Joint[mh] OR "Spinal Fractures"[mh] OR "Back Injuries"[mh] OR "Neck Injuries"[mh] OR "Spinal Cord Injuries"[mh] OR "Thoracic Injuries"[mh] OR "Spinal Diseases"[mh] OR "Lumbar Vertebrae"[mh] OR Spine[mh] OR Lumbosacral Region[mh] OR "Spinal Nerve Roots"[mh] OR "Zygapophyseal Joint"[mh]) AND (systematic review[sb] OR meta-analysis[mh] OR RCT OR randomized controlled trial OR "Randomized Controlled Trial"[mh])) AND ("2017/08/01"[PDAT] : "3000"[PDAT]) AND human[mh] AND English[Language] NOT clinical protocols[mh] NOT "protocol" NOT "Animal Population Groups"[mh] NOT Neoplasms[mh] NOT cancer [sb] NOT child[mh] NOT Adolescent[mh] NOT "Cost-Benefit Analysis"[mh] NOT "healthy volunteers"[mh] NOT "Case-control studies"[mh]

PHASES OF THE MTG PROCESS

▶ **Finding and selecting studies**

▶ Inclusion / exclusion criteria


- ▶ RCT or SR/MA of RCTs

- ▶ Published in a peer-reviewed journal in English

- ▶ Fits our scope (PICOTs)

- ▶ Sufficient size (20 subjects per group)

STUDY TYPE



PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ Finding and selecting studies
- ▶ **Evaluating individual studies**
- ▶ Combining evidence from multiple studies
- ▶ Writing recommendations and guidance
- ▶ Task Force process
- ▶ Advisory Panel and public input process

PHASES OF THE MTG PROCESS

▶ **Evaluating individual studies**

- ▶ Which results are we interested in?
 - ▶ Direct comparison of the amount of change
- ▶ How confident are we that those results represent the true effect of the treatment?
 - ▶ Risk of bias – many factors can potentially bias the results
 - ▶ We currently use Cochrane's updated risk-of-bias tool (RoB 2)
 - ▶ Also called “internal validity”

PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ Finding and selecting studies
- ▶ Evaluating individual studies
- ▶ **Combining evidence from multiple studies**
- ▶ Writing recommendations and guidance
- ▶ Task Force process
- ▶ Advisory Panel and public input process

PHASES OF THE MTG PROCESS

▶ **Combining evidence from multiple studies**

▶ Systematic review – the “qualitative” questions:

▶ Which studies can be combined based on their scope (PICOs)?

▶ For example: Different age ranges; Different methods of delivering the treatment; Different outcome measures

▶ Do the study results agree?

▶ If not, look for explanations of the inconsistency.

PHASES OF THE MTG PROCESS

▶ **Combining evidence from multiple studies**

▶ Meta-analysis – the “quantitative” analysis:

▶ Results in a “pooled estimate” of the effect

▶ Is there evidence of publication bias (unpublished studies)?

▶ Do any low-quality studies bias the pooled estimate?

▶ How certain is the pooled estimate (confidence interval)?

PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ Finding and selecting studies
- ▶ Evaluating individual studies
- ▶ Combining evidence from multiple studies
- ▶ **Writing recommendations and guidance**
- ▶ **Task Force process**
- ▶ Advisory Panel and public input process

PHASES OF THE MTG PROCESS

- ▶ **Writing recommendations and guidance**
- ▶ **Task Force process**
 - ▶ Consider multiple factors that go into recommendations:
 - ▶ Study results
 - ▶ Risks/harms
 - ▶ Other factors like availability and cost
 - ▶ Expert perspectives

PHASES OF THE MTG PROCESS

- ▶ **Writing recommendations and guidance**
- ▶ **Task Force process**
 - ▶ Consider details that inform the guidance around recs:
 - ▶ Study population and condition – informs the indications
 - ▶ Details of the study treatment – informs dose and duration
 - ▶ Other factors like co-interventions in the studies

PHASES OF THE MTG PROCESS

- ▶ Expert interviews and scoping
- ▶ Finding and selecting studies
- ▶ Evaluating individual studies
- ▶ Combining evidence from multiple studies
- ▶ Writing recommendations and guidance
- ▶ Task Force process
- ▶ **Advisory Panel and public input process**

PHASES OF THE MTG PROCESS


▶ **Advisory Panel and public input process**

- ▶ 35 member Advisory panel for the spine guidelines
- ▶ Public comment period of at least 1 month
 - ▶ Actively solicit input by emailing all prior stakeholders



Study design

STUDY TYPE



CASE REPORTS AND CASE SERIES

- ▶ One or more people with a particular condition are given a treatment and improve
- ▶ Strengths:
 - ▶ Hypothesis generating about possibly effective treatments
 - ▶ Provides information about possible dose, duration, etc.

CASE REPORTS AND CASE SERIES

- ▶ Limitations:
 - ▶ Only positive results usually get reported
 - ▶ The authors often have a vested interest in the treatment
 - ▶ Many factors other than the treatment could be the reason for improvement
 - ▶ No control comparison

CROSS-SECTIONAL STUDIES

- ▶ All information is gathered at one point in time
- ▶ Surveys are typical, though some include other data collection
- ▶ Used more to investigate risk factors than treatments
- ▶ Diagnostic studies are similar:
 - ▶ Results of the diagnostic tool being studied are compared with results of a gold-standard diagnosis

CASE-CONTROL STUDIES

- ▶ Used most often to look for links between risk factors and diseases
- ▶ Cases are individuals who developed the disease
- ▶ Controls are selected from a similar population, often matched for key demographics
- ▶ The history of possible risk factors are compared
- ▶ Not relevant for evaluating treatments

COHORT STUDIES

- ▶ Two groups with a key difference at the starting point are followed over time to detect possible outcomes
 - ▶ For example: people who got a certain treatment vs. others who didn't get that treatment are followed for improvement
 - ▶ More commonly used to link risk factors and disease

COHORT STUDIES

- ▶ Strengths:
 - ▶ Less expensive and less red tape than a trial
 - ▶ Can be used when randomization isn't feasible
- ▶ Limitations:
 - ▶ Much greater risk of bias, especially related to the selection of who is in each group

COMPARATIVE TRIAL (INCLUDING RCTs)

- ▶ Divide patients with a condition into two groups: treatment A vs treatment B
- ▶ Randomized – each individual has an equal chance of being in each group. This eliminates possible selection bias.
- ▶ Controlled – treatment B is a “control.” Thus, if group A improves more than group B, it’s reasonable to conclude it’s from treatment A.

COMPARATIVE TRIALS (INCLUDING RCTs)

- ▶ Strengths of RCTs:
 - ▶ If well designed and executed, eliminates many possible sources of bias.
 - ▶ Is therefore the strongest study type to demonstrate causation.

COMPARATIVE TRIALS (INCLUDING RCTs)

- ▶ Limitations of RCTs:
 - ▶ Expensive.
 - ▶ Recruitment can be difficult.
 - ▶ Can be “underpowered” due to small numbers.
 - ▶ Many requirements to ensure ethical study practices.
 - ▶ Must balance getting similar groups with representing the general population.

SYSTEMATIC REVIEWS AND META-ANALYSES

- ▶ Systematic review
 - ▶ Formal, rigorous methods to identify all relevant research (such as our MTG process)
- ▶ Non-systematic review examples
 - ▶ The latest studies receiving press coverage
 - ▶ A selection of research provided by a drug representative or device manufacturer

SYSTEMATIC REVIEWS AND META-ANALYSES

- ▶ Meta-analysis
 - ▶ Statistical combination of study results to generate a “pooled” estimate of effect
- ▶ Our confidence in the findings of systematic reviews and meta-analyses **depend on the quality of the included studies**



(Minimizing)
Risk of Bias

RANDOM SEQUENCE GENERATION

- ▶ Determines a random order for assigning people into the intervention and control groups
- ▶ Occurs at the start of the trial before allocation
- ▶ Helps to eliminate confounders
 - ▶ Confounder = a difference in some characteristic between the groups that affects outcomes
- ▶ Avoids **selection bias**

ALLOCATION CONCEALMENT

- ▶ When a person is recruited to the study, no one can predict which group they will be allocated to
- ▶ Ensures the strict implementation of the random sequence
 - ▶ Prevents changing the order
 - ▶ Prevents selecting who to recruit based on knowledge of which group they would be in
- ▶ Avoids **selection bias**

BLINDING OF PARTICIPANTS & PROVIDERS

- ▶ Patients don't know which group they are in for the duration of the study – and neither do their providers
- ▶ Ensures there are not differences in additional treatments or patient behaviors resulting from knowledge of group assignment
- ▶ Avoids **performance bias**
- ▶ In some cases, blinding might not be possible

BLINDING OF OUTCOME ASSESSMENT

- ▶ Individuals measuring the outcomes don't know which group each patient is in
- ▶ Prevents psychological biasing of outcome measurement, especially any that are subjective
- ▶ The patient may also be an outcome assessor
- ▶ Avoids **detection bias**

SUFFICIENT FOLLOW-UP

- ▶ There isn't a firm rule, but 95% is generally good
- ▶ Can be hard to control lost patients & data
 - ▶ Patient withdrawal or loss to follow up
 - ▶ Missing data, such as incomplete assessments
- ▶ Could “missingness” be related to outcomes for those patients?
- ▶ Avoids **attrition bias**

FULL REPORTING AND APPROPRIATE ANALYSIS

- ▶ Outcome measures are appropriate
- ▶ All outcome measures are reported
 - ▶ No selective reporting
- ▶ Analysis should be based on group assignment (intention-to-treat)
 - ▶ If multiple analyses were done, all are reported
- ▶ Avoids **reporting bias**

PRE-REGISTERED STUDY PROTOCOL

- ▶ This is becoming standard practice
- ▶ A protocol should be registered prior to enrollment
- ▶ There should be no major changes in study design from the early protocol to the final study report
- ▶ Provides assurance against multiple types of potential bias



Any questions?



daniel.vigil@
state.co.us

(or via Dr. Cook-Shimaneck)